10-Q: Upexi Inc. Reports Q2 2025 Results: Revenue Declines Amid Strategic Shift, Net Loss Narrows

Upexi Inc.'s Q2 2025 results reveal a revenue decrease due to a strategic shift away from recommerce, though the net loss has narrowed compared to the previous year.

Summary

• Upexi Inc. reported a net loss of $1.3 million for the three months ended December 31, 2024, compared to a net loss of $2.4 million for the same period in 2023.
• Revenue decreased by 46% to $4.0 million from $7.5 million year-over-year, primarily due to a strategic shift away from the recommerce business.
• The company's gross profit margin increased to 74% compared to 61% in the same period last year.
• For the six months ended December 31, 2024, the net loss was $2.9 million, compared to $3.8 million for the same period in 2023.
• Revenue for the six months ended December 31, 2024, declined by 47% to $8.4 million from $15.7 million year-over-year.
• The company is focusing on product sales, including the development, production, and distribution of branded products.
• The company had cash of $406,347 on December 31, 2024, a decrease of $255,068 from June 30, 2024.
• The company's ability to continue as a going concern is dependent upon generating profitable operations and/or obtaining necessary financing.
• The company identified material weaknesses in internal control over financial reporting related to inadequate segregation of duties and lack of multiple levels of supervision and review.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While the company's revenue declined, the net loss narrowed and gross profit margin increased. The company is also focusing on higher-margin branded products and reducing costs. However, the company's ability to continue as a going concern is dependent upon generating profitable operations and/or obtaining necessary financing.

Positives

• The company's net loss narrowed for both the three and six months ended December 31, 2024, compared to the same periods in 2023.
• Gross profit margin increased to 74% for the three months ended December 31, 2024, compared to 61% for the same period in 2023.
• Sales and marketing expenses decreased by 36% for the three months ended December 31, 2024, compared to the same period last year.
• Distribution costs decreased by 49% for the three months ended December 31, 2024, compared to the same period last year.
• Other expenses, primarily interest, decreased by 78% for the three months ended December 31, 2024, compared to the same period last year.

Negatives

• Revenue decreased by 46% for the three months ended December 31, 2024, compared to the same period in 2023.
• The company had a working capital deficit of $4.5 million as of December 31, 2024.
• The company's cash balance decreased by $255,068 from June 30, 2024.
• The company identified material weaknesses in internal control over financial reporting related to inadequate segregation of duties and lack of multiple levels of supervision and review.

Risks

• The company's ability to continue as a going concern is dependent upon generating profitable operations and/or obtaining necessary financing.
• The company's strategic plan will require additional capital in the near term.
• The company identified material weaknesses in internal control over financial reporting related to inadequate segregation of duties and lack of multiple levels of supervision and review.
• The potential dilution remains a risk, and is the subject of a complaint filed by the Company in the United States District Court for the District of Nevada with the purpose of eliminating any said risk.

Future Outlook

Management intends to finance operating costs over the next twelve months with existing cash on hand, cash flow from operations, proceeds from the sale of VitaMedica not yet received and additional short term debt financings, if necessary, estimating sufficient working capital to fund operations and meet debt obligations.

Management Comments

• Management has augmented the overall strategy of the Company to focus on product sales, including the development, production and distribution of branded products.
• Management expects the trend to continue with the focus on sales of branded products.
• Management will continue to reduce overall distribution costs with the consolidation of products and facilities.
• Management expects that general and administrative expenses to continue to decline, with the most significant declines being realized in periods ending after December 31, 2024.

Industry Context

The strategic shift away from recommerce reflects a broader trend in the e-commerce industry where companies are focusing on higher-margin branded products to improve profitability.

Comparison to Industry Standards

• The company's gross profit margin of 74% is relatively high compared to industry averages, suggesting a focus on higher-margin products.
• Comparable companies in the consumer products sector, such as Procter & Gamble and Unilever, typically have gross profit margins in the range of 50-60%.
• The company's revenue decline is significant and may be a cause for concern, as it lags behind the growth rates of other e-commerce companies.
• Companies like Amazon and Shopify have experienced revenue growth in recent years, driven by increased online sales and the expansion of their services.

Legal Proceedings

• Get Fit Fast Supplements, LLC, filed a lawsuit against Cygnet Online, LLC, et al., including, but not limited to the Company and Eric Hanig.
• The case is presently in active arbitration and is styled Get Fit Fast Supplements, LLC v. Cygnet Online, LLC, et al., American Arbitration Association Case No. 01-24-0003-1085.
• The parties are seeking monetary damages in their various claims and counterclaims against one another.
• The Company is vigorously defending all claims made against it in the case.

Related Party Transactions

• In June 2024, Allan Marshall, the Company's CEO advanced the Company $100,000 to enable the Company to purchase equipment needed for the new warehouse facility.
• Subsequent to December 31, 2024, Mr. Marshall advanced the Company $400,000 to cover short term negative cash flow.
• On April 1, 2024, the Company entered into a lease agreement with MFA 2510 Merchant LLC, which is owned by our CEO, Allan Marshall.
• One of the minority interest buyers of VitaMedica, Inc. is Allan Marshall, the Company's CEO.
• In June 2022, the Company entered into a promissory note with a member of management.
• $1,000,000 of the principal was used as part of the VitaMedica purchase price.

Stakeholder Impact

• Shareholders: The revenue decline and working capital deficit may negatively impact shareholder value.
• Employees: The company's cost-cutting measures and strategic shift may impact employee roles and responsibilities.
• Customers: The focus on branded products may lead to changes in product offerings and pricing.
• Creditors: The company's ability to repay its debts is dependent upon generating profitable operations and/or obtaining necessary financing.

Next Steps

• The company plans to implement the appointment of additional qualified personnel to address inadequate segregation of duties and implement modifications to our financial controls to address such inadequacies, by the end of our 2025 fiscal year as resources allow.
• The company is currently reviewing its disclosure controls and procedures related to these material weaknesses and expect to implement changes in the current fiscal year, including identifying specific areas within our governance, accounting and financial reporting processes to add adequate resources to potentially mitigate these material weaknesses.
• Management intends to finance operating costs over the next twelve months from the date of the issuance of these consolidated financial statements with existing cash on hand, cash flow from operations, proceeds from the sale of VitaMedica not yet received and additional short term debt financings, if necessary.

Key Dates